Business Wire

BALDERTON-CAPITAL

17.11.2021 09:02:09 CET | Business Wire | Press release

Share
Balderton Capital Raises New $600m Early-stage Fund to Back Europe’s Next Wave of Breakout Tech

Balderton Capital has raised its second fund of 2021 – a $600m fund focused on early-stage companies – to support its mission to be the leading provider of venture capital and founder support to European startups with global ambitions.

With close to 300 investments made since the firm was founded 21 years ago, Balderton has extensive experience backing exceptional founders from seed to growth stage, Europe-wide. Since the start of the year, Balderton has invested in 20 new startups in sectors ranging from reproductive health and instant commerce to data labelling and gaming.

The firm has also seen 13 portfolio companies achieve unicorn status this year, underlining the fund’s long track record of picking category leaders early. Companies where Balderton invested at Seed or Series A, include Aircall, Beauty Pie, ComplyAdvantage, Contentful, Depop, Dream Games, GoCardless, Infarm, Labster, Revolut, Vestiaire Collective and Zego.

“Balderton Capital is a very different firm than it was 12 months ago. We have not only launched two new funds, but have grown and strengthened our team. We have entered a new era in which we will be able to operate at a different pace and with a broader view of when we can support founders. Our transition from Europe’s leading Series A investor to a multi-stage fund gives us more firepower and flexibility and helps us to uncover more hidden gems among Europe’s startups.” Bernard Liautaud, Managing Partner at Balderton Capital, said.

Balderton’s portfolio companies have collectively raised more than $6bn in follow-on funding this year to date, almost double the $3.1bn raised in the entirety of 2020. Four portfolio companies – Darktrace, Flywire, SOPHiA Genetics and Truecaller – have also gone public in landmark European IPOs and the firm has seen 10 exits, including Peakon’s sale to Workday , Nutmeg’s sale to JPMorgan Chase and Depop’s sale to Etsy .

“The launch of Fund VIII marks 21 years of seed and Series A investing at Balderton. In that time we have had the huge privilege to work with many irrepressible founders with outsized ambitions and we hope to do so once again.” said General Partner Suranga Chandratillake. “While our job may not have changed, Europe has - we are excited for the thriving ecosystem we find around us with more talent, more capital and more ambition than at any time in our history.”

Rana Yared, General Partner, added: “We pull out all the stops to help our founders be successful operationally, and by investing at both early stage and further down the line, we are also able to offer the long-term partnership and capital they need to help them achieve their ambitions. We are delighted to be able to support a new generation of entrepreneurs through this fund.”

Committed to European tech ambition

With Europe on track to raise a record $70bn of venture capital investment by the end of the year, more than twice the total for 2020, Balderton Capital has doubled down on its commitment to building the next generation of global tech companies from the region.

The firm is one of only a handful of genuinely pan-European investors with partners in key hubs across the region. The firm has raised four funds totalling close to $2bn since 2018 and has active investments in more than 100 companies, employing more than 26,000 people in 50 countries around the world.

The new fund will be sector agnostic and managed by Balderton’s investment team of 25 working across Europe. The equal partnership will work together to share experience and insights to the benefit of the entire portfolio.

Founder-focused

Balderton’s portfolio companies benefit from its Build with Balderton platform of talent, marketing, finance and legal services. The Platform is wholly focused on giving founding teams the help they need to scale, including access to operational and functional services and an active community of peers.

Balderton’s Platform continues to expand, and the firm has added 13 people to its team in the last year, including Dave Kellogg, Balderton’s first executive-in-residence. Founding teams also gain access to the global industry leaders of the Balderton Executive Council ; the CEO Collective offsite; and events and workshops hosted at the firm’s Kings Cross headquarters and across Europe.

Balderton has also reaffirmed its commitment to building a sustainable and fair venture firm by publishing its Sustainable Future Goals - 60 objectives designed to reduce its impact on the environment, increase its social diversity and improve its governance. Recognising the role that investors play in creating a more sustainable and equal economy, Balderton is sharing its SFGs with portfolio companies and working with them to take action to improve performance against the goals.

Balderton was also proud to be awarded Level 2 Certification of the Diversity VC Standard in 2021, meaning the firm is considered to be leading the way on Diversity and Inclusion policy.

About Balderton Capital:
Balderton Capital is Europe’s leading venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since its founding, Balderton has worked with hundreds of extraordinary European founders, and raised almost $4.5bn across ten funds. Previous exited investments include Betfair (FTSE: BET), Depop (Etsy), Digital Surgery (Medtronic), Frontier Car Group (OLX Group), Flywire (NASDAQ: FLYW), Nutmeg (JPMorgan Chase), Peakon (Workday), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Balderton’s current portfolio includes Aircall, Beauty Pie, Carwow, Citymapper, Contentful, ComplyAdvantage, Darktrace (LSE: DARK), Dream Games, GoCardless, Graphcore, Healx, Infarm, Kobalt Music, Labster, Lyst, Prodigy Finance, Revolut, Sophia Genetics (NASDAQ:SOPH), Tessian, THG (LSE: THG), Truecaller (Stockholm:TRUEB), VanMoof, Vestiaire Collective, Vivino and Zego.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye